These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 31703717)

  • 1. Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study.
    Simon TA; Boers M; Hochberg M; Baker N; Skovron ML; Ray N; Singhal S; Suissa S; Gomez-Caminero A
    Arthritis Res Ther; 2019 Nov; 21(1):228. PubMed ID: 31703717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
    Pawar A; Desai RJ; Solomon DH; Santiago Ortiz AJ; Gale S; Bao M; Sarsour K; Schneeweiss S; Kim SC
    Ann Rheum Dis; 2019 Apr; 78(4):456-464. PubMed ID: 30679153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infection outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: Results from a 10-year international post-marketing study.
    Simon TA; Suissa S; Skovron ML; Frisell T; Askling J; Michaud K; Pedro S; Strangfeld A; Meissner Y; Boers M; Hoffman V; Dominique A; Gomez A; Hochberg MC
    Semin Arthritis Rheum; 2024 Feb; 64():152313. PubMed ID: 38044241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignancy outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: Results from a 10-year international post-marketing study.
    Simon TA; Suissa S; Boers M; Hochberg MC; Skovron ML; Askling J; Michaud K; Strangfeld A; Pedro S; Frisell T; Meissner Y; Dominique A; Gomez A
    Semin Arthritis Rheum; 2024 Feb; 64():152240. PubMed ID: 37500379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study.
    Kim SC; Pawar A; Desai RJ; Solomon DH; Gale S; Bao M; Sarsour K; Schneeweiss S
    Semin Arthritis Rheum; 2019 Oct; 49(2):222-228. PubMed ID: 30967248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study.
    Ozen G; Pedro S; Schumacher R; Simon TA; Michaud K
    Arthritis Res Ther; 2019 Jun; 21(1):141. PubMed ID: 31174592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative safety of biologic versus conventional synthetic DMARDs in rheumatoid arthritis with COPD: a real-world population study.
    Hudson M; Dell'Aniello S; Shen S; Simon TA; Ernst P; Suissa S
    Rheumatology (Oxford); 2020 Apr; 59(4):820-827. PubMed ID: 31504972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abatacept and non-melanoma skin cancer in patients with rheumatoid arthritis: a comprehensive evaluation of randomised controlled trials and observational studies.
    Simon TA; Dong L; Suissa S; Michaud K; Pedro S; Hochberg M; Boers M; Askling J; Frisell T; Strangfeld A; Meissner Y; Khaychuk V; Dominique A; Maldonado MA
    Ann Rheum Dis; 2024 Jan; 83(2):177-183. PubMed ID: 37932010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Cardiovascular Risk of Abatacept and Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis With and Without Diabetes Mellitus: A Multidatabase Cohort Study.
    Kang EH; Jin Y; Brill G; Lewey J; Patorno E; Desai RJ; Kim SC
    J Am Heart Assoc; 2018 Jan; 7(3):. PubMed ID: 29367417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: A multi-database cohort study.
    Kim SC; Solomon DH; Rogers JR; Gale S; Klearman M; Sarsour K; Schneeweiss S
    Semin Arthritis Rheum; 2018 Dec; 48(3):399-405. PubMed ID: 29673963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study.
    Montastruc F; Renoux C; Dell'Aniello S; Simon TA; Azoulay L; Hudson M; Suissa S
    Rheumatology (Oxford); 2019 Apr; 58(4):683-691. PubMed ID: 30535094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV Disease.
    Jin Y; Kang EH; Brill G; Desai RJ; Kim SC
    J Rheumatol; 2018 Aug; 45(9):1240-1248. PubMed ID: 29764964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of Interstitial Lung Disease in Patients With Rheumatoid Arthritis Treated With Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs.
    Baker MC; Liu Y; Lu R; Lin J; Melehani J; Robinson WH
    JAMA Netw Open; 2023 Mar; 6(3):e233640. PubMed ID: 36939701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice.
    Huss V; Bower H; Wadström H; Frisell T; Askling J;
    Rheumatology (Oxford); 2022 May; 61(5):1810-1818. PubMed ID: 34324640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative safety of abatacept in rheumatoid arthritis with COPD: A real-world population-based observational study.
    Suissa S; Hudson M; Dell'Aniello S; Shen S; Simon TA; Ernst P
    Semin Arthritis Rheum; 2019 Dec; 49(3):366-372. PubMed ID: 30979397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of Hospitalized Infection and Initiation of Abatacept Versus Tumor Necrosis Factor Inhibitors Among Patients With Rheumatoid Arthritis: A Propensity Score-Matched Cohort Study.
    Chen SK; Liao KP; Liu J; Kim SC
    Arthritis Care Res (Hoboken); 2020 Jan; 72(1):9-17. PubMed ID: 30570833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting.
    Liang H; Danwada R; Guo D; Curtis JR; Kilpatrick RD; Hendrickson B; Islam SS
    RMD Open; 2019; 5(2):e001013. PubMed ID: 31673413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of hospitalized infections in older elderly patients with rheumatoid arthritis treated with tocilizumab or other biological/targeted synthetic disease-modifying antirheumatic drugs: Evaluation of data from a Japanese claims database.
    Harigai M; Fujii T; Sakai R; Igarashi A; Shoji A; Yamaguchi H; Iwasaki K; Makishima M; Yoshida A; Okada N; Yamashita K; Kawahito Y
    Mod Rheumatol; 2024 Feb; 34(2):287-296. PubMed ID: 37039670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment.
    Simon TA; Smitten AL; Franklin J; Askling J; Lacaille D; Wolfe F; Hochberg MC; Qi K; Suissa S
    Ann Rheum Dis; 2009 Dec; 68(12):1819-26. PubMed ID: 19054822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.
    Yun H; Xie F; Delzell E; Levitan EB; Chen L; Lewis JD; Saag KG; Beukelman T; Winthrop KL; Baddley JW; Curtis JR
    Arthritis Rheumatol; 2016 Jan; 68(1):56-66. PubMed ID: 26315675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.